What We Do
Commitment to Innovation
ET-traps is a novel therapeutic that targets pathologically elevated endothelin-1 levels in the body, bringing endothelin-1 and various markers of heart and kidney function back to non-disease levels without side effects.
Drug Development
We have discovered a potent therapy for chronic kidney disease, cardiovascular disease, and other diseases associated with pathologically elevated ET-1 levels such as diabetes and neurological disorders, with a low cost, low dosage drug with no side effects.